Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

TACTIVE-U: Badanie mające na celu zdobycie wiedzy na temat badanego leku (wepdegestrantu) podawanego z innymi lekami u osób z zaawansowanym rakiem piersi lub rakiem piersi z przerzutami. (Badanie dodatkowe C)

23 października 2026 zaktualizowane przez: Pfizer

TACTIVE-U: INTERWENCYJNE BADANIE BEZPIECZEŃSTWA I SKUTECZNOŚCI, FAZA 1B/2, OTWARTE BADANIE PARASOLOWE MAJĄCE NA CELU BADANIE TOLERANCJI, PK I AKTYWNOŚCI PRZECIWNOWOTWOROWEJ WEPDEGESTRANTU (ARV-471/PF-07850327), DOUSTNEJ PROTEOLIZY DOCELOWEJ W POŁĄCZENIU Z INNYMI LECZENIE PRZECIWNOWOTWOROWE U UCZESTNIKÓW W WIEKU 18 ŻYCIA I WIĘCEJ Z ZAAWANSOWANYM RAKIEM PIERSI ER+ LUB Z PRZErzutami, BADANIE PODSTAWOWE C (ARV-471 W POŁĄCZENIU Z SAMURACICLIBEM)

The purpose of this study is to learn about the safety and effects of the study medicine called vepdegestrant. The safety and effects of vepdegestrant will be see when given with other medicines. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat.

The study is seeking for participants who have breast cancer that:

  • is hard to treat (advanced) and may have spread to other organs (metastatic). is sensitive to hormonal therapy (it is called estrogen receptor positive).
  • is no longer responding to treatments taken before starting this study.

This study is divided into separate sub-studies.

For Sub-Study C:

All the participants will receive vepdegestrant and a medicine called samuraciclib.

Vepdegestrant and samuraciclib will be taken once in a day by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicine is safe and effective.

Participant will continue to take vepdegestrant and samuraciclib until:

  • their cancer is no longer responding, or
  • side effects become too severe.

They will have visits at the study clinic about every 4 weeks.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

C4891024 is a prospective, open-label, multicenter, Phase 1b/2 sub-study to evaluate the safety, antitumor activity, and PK of ARV-471 with samuraciclib in the treatment of participants with A/MBC. The sub-study is part of Umbrella platform, TACTIVE-U, comprising multiple sub-studies that independently evaluate ARV-471 in participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer. ARV-471 will act as the backbone therapy given in combination with other anticancer agents thought to have clinical relevance in ER+ breast cancer.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

11

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Bruxelles-capitale, Région de
      • Anderlecht, Bruxelles-capitale, Région de, Belgia, 1070
        • Institut Jules Bordet
    • Côte-d'or
      • Dijon, Côte-d'or, Francja, 21079
        • Centre Georges François Leclerc
    • Arkansas
      • Fayetteville, Arkansas, Stany Zjednoczone, 72703
        • Highlands Oncology Group
      • Rogers, Arkansas, Stany Zjednoczone, 72758
        • Highlands Oncology Group
      • Springdale, Arkansas, Stany Zjednoczone, 72762
        • Highlands Oncology Group
    • California
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Stanford Women's Cancer Center
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Clinical and Translational Research Unit (CTRU)
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Stanford Cancer Institute - Clinical Trials Office
    • Colorado
      • Fort Collins, Colorado, Stany Zjednoczone, 80524
        • UCHealth Poudre Valley Hospital
      • Fort Collins, Colorado, Stany Zjednoczone, 80528
        • UCHealth Harmony
      • Greeley, Colorado, Stany Zjednoczone, 80634
        • UCHealth Greeley Hospital
      • Loveland, Colorado, Stany Zjednoczone, 80538
        • UCHealth - Medical Center of the Rockies
    • Illinois
      • Shiloh, Illinois, Stany Zjednoczone, 62269
        • Memorial Hospital East
      • Shiloh, Illinois, Stany Zjednoczone, 62269
        • Siteman Cancer Center - Shiloh
    • Missouri
      • City of Saint Peters, Missouri, Stany Zjednoczone, 63376
        • Siteman Cancer Center - St Peters
      • Creve Coeur, Missouri, Stany Zjednoczone, 63141
        • Siteman Cancer Center - West County
      • Florissant, Missouri, Stany Zjednoczone, 63031
        • Siteman Cancer Center - North County
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Washington University School of Medicine - Siteman Cancer Center
      • St Louis, Missouri, Stany Zjednoczone, 63129
        • Siteman Cancer Center - South County
      • Roma, Włochy, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    • Lombardy
      • Monza, Lombardy, Włochy, 20900
        • Fondazione IRCCS San Gerardo dei Tintori

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Histological or cytological diagnosis of breast cancer. At time of enrollment this must not be amendable to surgical resection with curative intent (≥1% ER+ stained cells as per local practice on the most recent tumor biopsy HER2- tumor by IHC or in-situ hybridization per ASCO/CAP).
  • prior anticancer therapies: up to 2 lines of prior therapies for advanced/metastatic disease; 1 line of any CDK4/6 inhibitor-based regimen is required (in any setting eg adjuvant, metastatic)
  • at least 1 measurable lesion as defined by RECIST v1.1.
  • ECOG PS ≤1.

Exclusion Criteria:

  • visceral crisis at risk of life-threatening complications in the short term
  • known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
  • newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 28 days prior to enrollment in the of study.
  • history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
  • inflammatory breast cancer
  • impaired cardiovascular function or clinically significant cardiovascular diseases
  • concurrent administration of medications, food, or herb supplements that are strong inhibitors/inducers of CYP3A, strong CYP2D6 inhibitors and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
  • renal impairment, not adequate liver function and/or bone marrow function
  • known active infection

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: ARV-471 in combination with Samuraciclib

ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles

Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Inne nazwy:
  • ARV-471 / PF-07850327

Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Phase 1b: Number of Participants With Dose Limiting Toxicities
Ramy czasowe: 28 days

Dose Limiting Toxicities rate for ARV-471 in combination with Samuraciclib, estimated based on data from DLT-evaluable participants during the DLT observation period (Cycle 1).

28 days
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Ramy czasowe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

Steady-state Area under the plasma concentration versus time curve (AUCtau) of ARV-471 with and without coadministration of samuraciclib

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Ramy czasowe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

Steady-state Peak Plasma concentration ( Cmax) of ARV-471 with and without coadministration of samuraciclib

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Phase 2: Percentage of Participants With Objective Response by investigator assessment
Ramy czasowe: Up to approximately 1 year

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

Up to approximately 1 year
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Ramy czasowe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Single dose AUC0-72 of samuraciclib with and without coadministration of ARV 471.

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Ramy czasowe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Single dose Cmax of samuraciclib with and without coadministration of ARV 471.

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Phase 1b, Drug drug interaction and Phase 2: Evaluation of Safety and Tolerability of ARV-471 in combination with Samuraciclib
Ramy czasowe: First study drug dose through a minimum of 28 Days After Last study drug administration

AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to ARV-471 in combination with samuraciclib.

Laboratory test abnormalities as characterized by type, frequency, intensity (as graded by NCI CTCAE version 5.0), and timing.

Changes from baseline for the ECG parameters heart rate, QTcF, PR interval, and QRS complex will be summarized by treatment and time. The frequency of uncorrected QT values above 500 ms will be tabulated.

First study drug dose through a minimum of 28 Days After Last study drug administration
Phase 1b: To evaluate antitumor activity of ARV-471 in combination with samuraciclib
Ramy czasowe: Up to approximately 1 year

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

Up to approximately 1 year
Phase 1b and Phase 2: Duration of Response by investigator assessment.
Ramy czasowe: Up to approximately 1 year

Duration of Response (DoR) is defined for participants with confirmed OR (CR or PR) as the time from the first documentation of OR to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

Up to approximately 1 year
Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.
Ramy czasowe: Up to approximately 1 year

Clinical Benefit Response (CBR) is defined as the proportion of participants with Best Overall Response of confirmed CR or PR at any time, or Stable Disease (SD) ≥24 weeks

Up to approximately 1 year
Phase 1b and Phase 2: Progression Free Survival by investigator assessment.
Ramy czasowe: Up to approximately 1 year

Progression Free Survival (PFS) is defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurs first.

Up to approximately 1 year
Phase 1b and Phase 2: Plasma concentrations of ARV-471 and samuraciclib.
Ramy czasowe: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

To evaluate the plasma exposure of ARV-471 and samuraciclib when ARV-471 and samuraciclib are given in combination.

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Ramy czasowe: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

AUCtau of ARV-471 with and without co-administration of samuraciclib

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Ramy czasowe: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

Cmax of ARV-471 with and without co-administration of samuraciclib

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 2:ctDNA plasma quantitative changes from pre-treatment
Ramy czasowe: At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment

To assess changes from baseline levels in plasma ctDNA with treatment and to evaluate potential predictability of their associations with clinical outcomes.

At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment
Phase 2: To evaluate the correlation between TP53 mutation status and antitumor activity
Ramy czasowe: Screening

Participants classified on basis of pathological TP53 mutation detected or not detected.

Screening
Phase 2: Overall Survival
Ramy czasowe: Through study completion, up to approximately 3 year

Overall Survival (OS) is defined as the time from the date of first dose of study interventions to the date of death due to any cause

Through study completion, up to approximately 3 year

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Dyrektor Studium: Pfizer CT.gov Call Center, Pfizer

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

10 stycznia 2024

Zakończenie podstawowe (Rzeczywisty)

10 września 2026

Ukończenie studiów (Rzeczywisty)

10 września 2026

Daty rejestracji na studia

Pierwszy przesłany

16 października 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

4 listopada 2023

Pierwszy wysłany (Rzeczywisty)

9 listopada 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

27 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

23 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • C4891024
  • 2023-507125-41-00 (Identyfikator rejestru: CTIS (EU))
  • 2023 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .